Prognostic factors according to the treatment schedule in malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 4, Issue 11, 2009, Pages 1425-1430

  Ak, Guntulu ^a   Metintas, Selma ^a   Metintas, Muzaffer ^a   Yildirim, Huseyin ^a   Erginel, Sinan ^a   Kurt, Emel ^a   Alatas, Fusun ^a   Cadirci, Omer ^a  

^a University Medical School   (Turkey)

Author keywords

Malignant pleural mesothelioma; Prognostic factors; Treatment schedule

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MITOMYCIN C; PEMETREXED; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HYPOTHESIS; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 70449568619     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ba2033     Document Type: Article

References (24)

1. Robinson BWS, Musk AW, Lake AR. Malignant mesothelioma. Lancet 2005;366:397-408.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644.
3. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
4. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative longterm survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
5. Batirel HF, Metintas M, Caglar HB, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 2008;3:499-504.
6. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965.
7. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007;57:89-95.
8. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998;16:145-152.
9. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731.
10. Metintas M, Metintas S, Ucgun I, et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Res Med 2001;95:829-835.
11. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the malignant pleural mesothelioma (MS01): a multicentre randomized trial. Lancet 2008;371:1685-1694.
12. Metintas M, Ak G, Erginel S, et al. A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005: a single institution experience. Lung cancer 2007;55:379-387.
13. Schipper PH, Nichols FC, Thomse KM, et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008;85:257-264.
14. Borasio P, Berruti A, Bille A, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardio-thorac Surg 2008;33:307-313.
15. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-735.
16. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005;23:184-189.
17. Gelder TV, Damhuis RAM, Hoogsteden HC. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994;7:1035-1038.
18. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Cancer 1993;72:394-404.
19. De pangher Manzini V, Brollo A, Franceschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993;72:410-417.
20. Christensen BC, Godleski JJ, Roelofs CR, et al. Asbestos burden predicts survival in pleural mesothelioma. Environ Health Perspect 2008;116:723-726.
21. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008;61:235-243.
22. Cappia S, Righi L, Mirabelli D, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008; 130:58-64.
23. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008; 3:1317-1324.
24. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-2935.